×
About 6,498 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  2,162 results

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT03915379

Dec 3rd, 2021 - This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-67571244 in adult participants with relapsed or refractory acu...

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT04742634

Dec 1st, 2021 - The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with per...

Comparison of flow cytometry with other modalities in the diagnosis of myelodysplastic ...
https://doi.org/10.1111/ijlh.13771
International Journal of Laboratory Hematology; Pembroke JS, Joseph JE et. al.

Nov 30th, 2021 - The myelodysplastic syndromes (MDSs) are heterogeneous myeloid malignancies, conventionally diagnosed by cytomorphology and cytogenetics, with an emerging role for flow cytometry. This study compared the performance of a 4-parameter flow cytometry...

Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myel...
https://doi.org/10.1016/j.clml.2021.10.015
Clinical Lymphoma, Myeloma & Leukemia; Polprasert C, Niparuck P et. al.

Nov 30th, 2021 - Unexplained cytopenia (UC) and low-risk myelodysplastic syndrome (MDS) are distinguished mainly by morphologic dysplasia, which sometimes shows inter-observer discrepancy. We hypothesized that gene mutations are strong prognostic factors for these...

Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease...
https://doi.org/10.1053/j.seminhematol.2021.10.003
Seminars in Hematology; Oganesyan A, Hakobyan Y et. al.

Nov 23rd, 2021 - It has been established that individuals with myelodysplastic syndromes (MDS) have a higher frequency of systemic inflammatory disorders. On the other hand, patients with autoimmune diseases are at increased risk of MDS development. Both diseases ...

see more →

Guidelines  12 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 23rd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 4th, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Myelodysplastic syndromes: clinical practice guidelines in oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000017
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Attar E et. al.

Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...

see more →

Drugs  36 results see all →

Clinicaltrials.gov  149 results

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT03915379

Dec 3rd, 2021 - This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-67571244 in adult participants with relapsed or refractory acu...

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT04742634

Dec 1st, 2021 - The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with per...

CHIP/CCUS Natural History Protocol
https://clinicaltrials.gov/ct2/show/NCT04102423

Nov 22nd, 2021 - Clonal Hematopoiesis of Indeterminate Potential (CHIP) has been defined as the presence of a somatic pathogenic variant associated with hematological malignancy, with an allele fraction of at least 2%, without morphological evidence of bone marrow...

CPX-351 in Higher Risk Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT04273802

Nov 19th, 2021 - A phase I/II study of the efficacy of CPX-351 treatment in patients with higher risk myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure. CPX-351 is an advanced liposomal formulation of daunorubicin and cyta...

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT03399773

Nov 15th, 2021 - OUTLINE: Patients receive either regimen A or regimen B. REGIMEN A: Patients (18 through 45 years old) receive fludarabine intravenously (IV) over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo total body i...

see more →

News  234 results

Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL
https://www.onclive.com/view/treatment-landscape-shifts-away-from-chemotherapy-toward-targeted-approaches-in-all

Nov 22nd, 2021 - Traditional cytotoxic chemotherapy-containing regimens have been the backbone of treatment for adults with acute lymphoblastic leukemia (ALL) for decades. Common complications of traditional chemotherapy can be fatal and include infection, bleedin...

Investigators Tackle New NSCLC Target With Glutaminase Inhibitor
https://www.onclive.com/view/investigators-tackle-new-nsclc-target-with-glutaminase-inhibitor

Oct 6th, 2021 - Telaglenastat (CB-839), a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types. Now, investigators have launched the phase 2 KEAPSAKE trial to evaluate the agent in combination with stan...

Dr. David Steensma on Myelodysplastic Syndrome
https://www.onclive.com/view/dr-david-steensma-on-myelodysplastic-syndrome

Oct 6th, 2021 - David P. Steensma, MD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute discusses myelodysplastic syndromes. Myelodysplastic syndromes are increasingly recognized, with 30,000-35,000 new case...

Dr. Patel on Data From the MEDALIST Trial in Low-Risk MDS
https://www.onclive.com/view/dr-patel-on-data-from-the-medalist-trial-in-low-risk-mds

Oct 6th, 2021 - Prapti Patel, MD, assistant professor in the Department of Internal Medicine at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses data from the MEDALIST trial on the use of luspatercept-aamt (Reblozyl) in pat...

Dr. Steensma on the Utility of Venetoclax in MDS
https://www.onclive.com/view/dr-steensma-on-the-utility-of-venetoclax-in-mds

Oct 6th, 2021 - David P. Steensma, MD, associate professor of medicine, Harvard Medical School, clinical director, Center for Prevention of Progression, Edward P. Evans Chair in Myelodysplastic Syndromes Research, and institute physician, Dana-Farber Cancer Insti...

see more →

Patient Education  6 results see all →